Milestone® Pharmaceuticals to Present at Upcoming Conferences
Milestone Pharmaceuticals (NASDAQ: MIST) announced its participation in two upcoming healthcare conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Milestone Pharmaceuticals (NASDAQ: MIST) announced its participation in two upcoming healthcare conferences. CEO Joe Oliveto will conduct one-on-one meetings at the Wells Fargo Healthcare Conference in Boston (September 3-5, 2025) and deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York (September 8-10, 2025).
The H.C. Wainwright presentation will be webcast live on September 9 at 12:00 PM EDT, with a replay available for approximately 90 days on the company's website.
Details
News Market Reaction – MIST
On Aug 19, the day this news came out, MIST closed 1.76% below the previous close.
Data tracked by StockTitan Argus for the Aug 19 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place September 3 - 5, 2025, in Boston and will provide a corporate update at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8 – 10, 2025, in New York.
A webcast of the H.C. Wainwright presentation will be available on September 9 at 12:00 PM EDT. The webcast will be available to watch live and a replay will be available for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com.
If you are interested in meeting with the Milestone team during the conference, please reach out to your Wells Fargo or H.C. Wainwright representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.
Contact
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.